Live price temporarily unavailable.
OnKure Therapeutics (OKUR) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | $0 | — |
| Operating income | −$19.6M | −$39.8M | −$53.8M | −$36.9M | −$54.4M | −$63.0M |
| Net income | −$19.5M | −$39.8M | −$52.0M | −$35.3M | −$52.7M | −$59.5M |
| EPS (diluted) | −$4800.00 | −$1095.00 | −$1060.00 | −$124.41 | −$15.28 | −$4.40 |
| Balance sheet | ||||||
| Cash and equivalents | $53.6M | $124.7M | $19.9M | $29.9M | $110.8M | $59.0M |
| Total assets | $55.2M | $154.0M | $108.2M | $35.7M | $114.9M | $62.1M |
| Total liabilities | $4.62M | $6.81M | $8.21M | $7.75M | $11.1M | $5.93M |
| Shareholders' equity | −$42.1M | $147.2M | −$54.4M | −$101.8M | $103.8M | $56.2M |
| Cash flow | ||||||
| Operating cash flow | −$18.5M | −$38.0M | −$47.4M | −$34.5M | −$51.1M | −$51.8M |
| Capital expenditure | $24.0K | $198.0K | $346.0K | $246.0K | $52.0K | $46.0K |
| Free cash flow | −$18.6M | −$38.2M | −$47.7M | −$34.8M | −$51.2M | −$51.9M |
| Share buybacks | — | — | — | $4.40M | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$11.5M | −$18.7M | −$17.0M | −$16.3M | −$15.5M | −$14.1M | −$15.6M | −$16.9M |
| Net income | −$11.6M | −$17.4M | −$15.9M | −$15.4M | −$14.7M | −$13.5M | −$15.2M | −$15.3M |
| EPS (diluted) | −$36.55 | $96.46 | −$1.19 | −$1.14 | −$1.09 | −$0.98 | −$1.11 | −$0.31 |
| Balance sheet | ||||||||
| Cash and equivalents | $60.7M | $110.8M | $96.7M | $83.4M | $70.3M | $59.0M | $192.1M | $166.5M |
| Total assets | $77.6M | $114.9M | $99.9M | $86.1M | $72.8M | $62.1M | $198.7M | $179.4M |
| Total liabilities | $3.63M | $11.1M | $9.23M | $7.90M | $6.41M | $5.93M | $14.3M | $7.25M |
| Shareholders' equity | −$135.1M | $103.8M | $90.6M | $78.2M | $66.4M | $56.2M | $184.4M | $172.1M |
| Cash flow | ||||||||
| Operating cash flow | −$10.7M | −$23.4M | −$14.0M | −$13.3M | −$13.0M | −$11.5M | −$12.9M | −$10.4M |
| Capital expenditure | $18.0K | $15.0K | $18.0K | $13.0K | $6.00K | $9.00K | $5.00K | $3.00K |
| Free cash flow | −$10.7M | −$23.4M | −$14.0M | −$13.3M | −$13.0M | −$11.5M | −$12.9M | −$10.4M |
From OnKure Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning OnKure Therapeutics in our feed yet.